After scrapping initial SPAC deal, Longevity Bio
Author: Michael
GC Therapeutics’ plug-and-play stem cell progr
Global industry leaders converge in Singapore to
As the International Longevity Summit approaches
Phase 2 study data indicates ‘dose-dependent i
Company aims to inhibit SARM1 enzyme to prevent
Designed to protect key retinal cells, company’s Fas inhibitor drugs aim to prevent vision loss in a range of conditions. With the world buzzing about Neuralink’s latest project to restore sight to the blind, others take the view that prevention is better than cure. To that end, US biopharma ONL Therapeutics has completed an oversubscribed $65 million Series D financing round to advance the clinical development of its novel therapeutics aimed at protecting retinal cells. ONL’s approach is focused on inhibiting Fas-mediated cell death, a critical mechanism in many ophthalmic diseases. Fas signaling plays a dual role in activating cell death and…
Collaboration aims to empower health practitione
Coya Therapeutics is pioneering multi-pathway th
Elon Musk claims that experimental ‘Blindsight